6.2. prognostic markers. 6.2.1. histopathological clinical markers important histopathological prognostic variables rc ln dissection tumour stage ln status . addition, histopathological parameters rc specimen associated prognosis. value lymphovascular invasion reported systematic review meta-analysis including 78,000 patients 65 studies treated rc bc . lymphovascular invasion present 35% patients correlated 1.5-fold higher risk recurrence csm, independent pathological stage peri-operative chemotherapy. correlation even stronger patients node-negative disease . systematic review meta-analysis including 23 studies 20,000 patients, presence concomitant cis rc specimen associated higher odds ratio (or) ureteral involvement (pooled or: 4.51, 2.59–7.84). concomitant cis independently associated os, recurrence-free survival (rfs) dss patients, patients organ-confined disease concomitant cis associated worse rfs (pooled hr: 1.57, 1.12–2.21) csm (pooled hr: 1.51, 1.001–2.280) . tumour location associated prognosis. tumours located bladder neck trigone bladder appear increased likelihood nodal metastasis (or: 1.83, 95% ci: 1.11–2.99) associated decreased survival [205, 208-210]. prostatic urethral involvement time rc also found associated worse survival outcomes. series 995 patients, prostatic involvement recorded 31% patients. 5-year css patients cis prostatic urethra 40%, whilst prognosis patients uc invading prostatic stroma worse 5-year css 12% . neutrophil-to-lymphocyte ratio (nlr) emerged prognostic factor uut tumours non-urological malignancies. pooled analysis 21 studies analysing prognostic role nlr bc, authors correlated elevated pre-treatment nlr os, rfs disease-free survival (dfs) localised metastatic disease . contrast, secondary analysis southwest oncology group (swog) 8710 trial, randomised phase iii trial assessing cystectomy ± nac patients mibc, suggests nlr neither prognostic predictive biomarker os mibc . patients ln-positive disease, american joint committee cancer (ajcc)-tnm staging system provides 3 subcategories. addition, several prognostic ln-related parameters reported. include, limited to, number positive lns, number lns removed, ln density (the ratio positive lns number lns removed) extranodal extension. systematic review meta-analysis, reported ln density independently associated os (hr: 1.45, 95%, ci: 1.11–1.90) . suggested ln density outperforms ajcc-tnm staging system ln-positive disease terms prognostic value . however, spite studies supporting use ln density, ln density relies number lns removed which, turn, subject surgical pathological factors. makes concept ln density difficult apply uniformly . two studies investigated whether reported ln-related parameters may superior routinely used ajcc-tnm staging system . whilst conclusion ajcc-tnm staging system ln status perform well, none tested variables outperformed ajcc system. 6.2.2. molecular markers 6.2.2.1. molecular variants based cancer genome atlas cohort updated cancer genome atlas (tcga) reported 412 mibcs identified two main groups; luminal basal-squamous - consisting five mrna expression-based molecular variant including luminal- papillary, luminal-infiltrated, luminal; basal-squamous; neuronal; variant associated poor survival part tumours small cell neuroendocrine histology. variant associated distinct mutational profiles, histopathological features prognostic treatment implications . basal-squamous variant characterised expression basal keratin markers, immune infiltrates felt chemosensitive. different luminal variants characterised fibroblast growth factor receptor 3 (fgfr3) alterations (luminal-papillary [lump]), epithelial-mesenchymal transition (emt) markers (luminal-infiltrated) may associated chemotherapy resistance . 2019, consensus molecular variant classification reported . authors analysed 1,750 mibc transcriptomic profiles 18 datasets identified six mibc molecular classes reconcile previously published classification schemes. molecular variant classes include lump, luminal non-specified (lumns), luminal unstable (lumu), stroma-rich, basal/squamous (ba/sq), neuroendocrine-like (ne-like). class distinct differentiation patterns, oncogenic mechanisms, tumour micro-environments histological clinical associations. however, authors stressed consensus reached biological rather clinical classes. therefore, time, classification considered research tool retrospective prospective studies future studies establish molecular variants used best clinical setting. molecular classification mibc still evolving treatment tailored molecular variant standard yet. novel 12-gene signature derived patients tcga utilising published gene signatures developed externally validated predict os mibc . interestingly, analysis molecular typing mibc demonstrated although molecular variants reflect heterogeneity bladder tumours associated tumour grade, clinical parameters outperformed variants predicting outcome . coming years, new insights bc carcinogenesis may change management disease ability better predict outcomes . outside clinical trials, molecular examination, either expression profiling immunohistochemistry, yet part routine clinical work-up awaiting conclusive data.